Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period. (2019)

First Author: Portale AA
Attributed to:  Centre for Integrated research into Musculoskeletal Ageing (CIMA) Renewal funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s00223-019-00568-3

PubMed Identifier: 31165191

Publication URI: http://europepmc.org/abstract/MED/31165191

Type: Journal Article/Review

Volume: 105

Parent Publication: Calcified tissue international

Issue: 3

ISSN: 0171-967X